Targeting the PI3K/AKT/PTEN Pathway for Treatment of Breast Cancer: Innovative Solutions for Equitable Care

Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.

Program Overview
The PI3K/AKT/PTEN pathway has emerged as a key player in breast cancer development. Notably, up to 50% of patients with hormone receptor"positive, human epidermal growth factor receptor 2"negative (HR+/HER2-) breast cancer have actionable biomarkers within this pathway, paving the way for novel approaches to management. This CME/CE activity will cover emerging therapeutic strategies for HR+/HER2- breast cancer that target the PI3K/AKT/PTEN pathway as well as best practices for enhancing early detection and management of treatment-related adverse events. Experts will also discuss ways to improve adherence to therapy and care coordination among rural and underserved populations using a multidisciplinary approach.

This enduring activity is a recorded session from Oncology Congress that took place on September 28, 2024.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Evaluate the efficacy and safety of current and emerging treatments for breast cancer that target the PI3K/AKT/PTEN pathway
Identify patients who may be eligible for treatment with inhibitors of the PI3K/AKT/PTEN pathway
Apply evidence-based strategies and best practices to identify, monitor, and manage adverse events associated with PI3K/AKT/PTEN pathway inhibitors
Develop a multidisciplinary approach to improve treatment adherence and care coordination in breast cancer, considering the unique challenges faced by rural and underserved populations